APhA, in a formal comment letter, reiterated its concerns with FDA's list of drugs that present demonstrable difficulties for compounding. APhA's concerns include the agency's decision to identify ...

seeking to put the drug on an FDA list of compounds deemed to be difficult to compound, but has so far been unsuccessful. The new move comes as Eli Lilly has also taken action against compounders ...

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity ...

The FDA says compounding pharmacies, which make similar versions of name-brand drugs like Ozempic and Wegovy, will no longer be allowed to sell them after the end of April and May. In 2022 ...

On June 7, 2002, the FDA issued a compliance policy guidance to FDA staff and the drug compounding industry to explain how it will regulate pharmacy compounding in the immediate future in light of ...

Kennedy, Jr., the U.S. Food and Drug Administration unveiled the Chemical Contaminants Transparency Tool (CCT Tool), an online searchable database providing a consolidated list of contaminant ...

To address this issue, the signatories urge FDA to take the following action: Enforce Existing Regulations: Ensure that compounding pharmacies adhere to federal regulations by discontinuing the ...

compounding pharmacy plaintiffs argued that the FDA arbitrarily removed Eli Lilly’s weight loss drug tirzepatide from the drug shortage list. The compounding pharmacies sought a preliminary ...